Cumulus Neuroscience
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Concourse, 3 Queens Road, Belfast, Antri...Phone Number
+44 2892646600Website
www.cumulusneuro.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cumulus Neuroscience
Cumulus Neuroscience develops an advanced at-home medical grade platform designed to address healthcare challenges in neurodegeneration and psychiatry. Their innovative tools focus on improving the monitoring and assessment of brain health by utilizing neurophysiological monitoring (EEG) and various cognitive assessments. Targeting pharmaceutical companies and clinical trial partners, Cumulus provides critical insights for more effective drug discovery and patient therapy delivery. The platform incorporates machine learning analytics, allowing for the rapid generation of meaningful data to enhance clinical outcomes.Explore more
Cumulus Neuroscience Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cumulus Neuroscience your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Cumulus Neuroscience launches new products
Funding: Get notified immidiatlly once Cumulus Neuroscience has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Cumulus Neuroscience is spiking on competitors!
Check if Cumulus Neuroscience has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cumulus Neuroscience had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cumulus Neuroscience
Earning: See what the market has to say on Cumulus Neuroscience recently announced quarterly report
Cumulus Neuroscience, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Cumulus Neuroscience
Find 2 more new buyers
Compare Similar Companies to Cumulus Neuroscience
Compare insights from companies similar to Cumulus Neuroscience, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cumulus Neuroscience is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cumulus Neuroscience is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cumulus Neuroscience.
Cumulus Neuroscience financials insights
Gather financial insights about Cumulus Neuroscience, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Other Financing Round
$8.3M
2024
Other Financing Round
$14M
2025
Other Financing Round
$4.4M
Cumulus Neuroscience Tech Stack
A closer look at the technologies used by Cumulus Neuroscience
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Healthcare Technology
Person-Based
Partnership, Medical Research, Clinical Operations, Healthcare Technology
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Cumulus Neuroscience News & Media
Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
Final results from the CNS-102 study, published in Scientific Reports, show that the at-home NeuLogiq® Platform can be deployed successfully in patients with significant motor and cognitive impairment — with 82% of ALS participants rating the platform easy to use and 75% rating their...Cumulus Neuroscience Presents Data at AAIC 2026 Annual Meeting Showing a Two-Minute Digital Task Matches or Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment
Across three independent studies, the NeuLogiq® Platform two-minute tablet-based Symbol Swap task delivered clinically meaningful discrimination between control, MCI and Alzheimer's dementia groups and detected blood-biomarker-defined pathology — including in clinically normal individuals...Cumulus Neuroscience and Muse by Interaxon Bring Validated At-Home Sleep EEG to CNS Clinical Trials
Collaboration adds brain-based sleep measurement to the NeuLogiq® multi-modal platform BELFAST, Northern Ireland, DUBLIN and TORONTO, July 6, 2026 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials...Cumulus Neuroscience Announces Publication in Frontiers in Digital Health Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home Cognitive and EEG Assessment in People Living with Mild Alzheimer's Disease Dementia
Final results from the CNS-101 study, published in Frontiers in Digital Health, show that the NeuLogiq Platform can be used successfully over a full year by patients living with mild Alzheimer's disease dementia. Patients in the study completed 99.7% of initiated sessions and maintained...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Cumulus Neuroscience
Sign Up For FreeTo access detailed company insights
Cumulus Neuroscience develops an advanced at-home medical grade platform designed to address healthcare challenges in neurodegeneration and psychiatry. Their innovative tools focus on improving the monitoring and assessment of brain health by utilizing neurophysiological monitoring (EEG) and various cognitive assessments. Targeting pharmaceutical c... Read More
